Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Spatial access to syringe exchange programs and pharmacies selling over-the-counter syringes as predictors of drug injectors' use of sterile syringes.

Cooper HL, Des Jarlais DC, Ross Z, Tempalski B, Bossak B, Friedman SR.

Am J Public Health. 2011 Jun;101(6):1118-25. doi: 10.2105/AJPH.2009.184580. Epub 2010 Nov 18.

2.

Spatial access to sterile syringes and the odds of injecting with an unsterile syringe among injectors: a longitudinal multilevel study.

Cooper H, Des Jarlais D, Ross Z, Tempalski B, Bossak BH, Friedman SR.

J Urban Health. 2012 Aug;89(4):678-96. doi: 10.1007/s11524-012-9673-y.

3.

Temporal trends in spatial access to pharmacies that sell over-the-counter syringes in New York City health districts: relationship to local racial/ethnic composition and need.

Cooper HL, Bossak BH, Tempalski B, Friedman SR, Des Jarlais DC.

J Urban Health. 2009 Nov;86(6):929-45. doi: 10.1007/s11524-009-9399-7.

4.

Access to syringes in three Russian cities: implications for syringe distribution and coverage.

Sarang A, Rhodes T, Platt L.

Int J Drug Policy. 2008 Apr;19 Suppl 1:S25-36. doi: 10.1016/j.drugpo.2007.11.008. Epub 2008 Mar 3.

PMID:
18313910
5.

Syringe disposal among people who inject drugs in Los Angeles: the role of sterile syringe source.

Quinn B, Chu D, Wenger L, Bluthenthal RN, Kral AH.

Int J Drug Policy. 2014 Sep;25(5):905-10. doi: 10.1016/j.drugpo.2014.05.008. Epub 2014 May 21.

PMID:
24930425
6.

Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal.

Neaigus A, Zhao M, Gyarmathy VA, Cisek L, Friedman SR, Baxter RC.

J Urban Health. 2008 May;85(3):309-22. doi: 10.1007/s11524-008-9271-1. Epub 2008 Mar 14.

7.

Comparison of injection drug users accessing syringes from pharmacies, syringe exchange programs, and other syringe sources to inform targeted HIV prevention and intervention strategies.

Rudolph AE, Crawford ND, Ompad DC, Benjamin EO, Stern RJ, Fuller CM.

J Am Pharm Assoc (2003). 2010 Mar-Apr 1;50(2):140-7. doi: 10.1331/JAPhA.2010.09193.

8.

Pharmacy access to syringes among injecting drug users: follow-up findings from Hartford, Connecticut.

Singer M, Baer HA, Scott G, Horowitz S, Weinstein B.

Public Health Rep. 1998 Jun;113 Suppl 1:81-9.

9.

Expanding access to sterile syringes through pharmacies: assessment of New York's Expanded Syringe Access Program.

Tesoriero JM, Battles HB, Klein SJ, Kaufman E, Birkhead GS.

J Am Pharm Assoc (2003). 2009 May-Jun;49(3):407-16. doi: 10.1331/JAPhA.2009.07127.

PMID:
19443321
10.

Drug-related arrest rates and spatial access to syringe exchange programs in New York City health districts: combined effects on the risk of injection-related infections among injectors.

Cooper HL, Des Jarlais DC, Tempalski B, Bossak BH, Ross Z, Friedman SR.

Health Place. 2012 Mar;18(2):218-28. doi: 10.1016/j.healthplace.2011.09.005. Epub 2011 Sep 28.

11.

Effects of increasing syringe availability on syringe-exchange use and HIV risk: Connecticut, 1990-2001.

Heimer R, Clair S, Teng W, Grau LE, Khoshnood K, Singer M.

J Urban Health. 2002 Dec;79(4):556-70.

12.

Sterile syringe access conditions and variations in HIV risk among drug injectors in three cities.

Bluthenthal RN, Malik MR, Grau LE, Singer M, Marshall P, Heimer R; Diffusion of Benefit through Syringe Exchange Study Team.

Addiction. 2004 Sep;99(9):1136-46.

PMID:
15317634
13.

Pharmacy access to sterile syringes for injection drug users: attitudes of participants in a syringe exchange program.

Junge B, Vlahov D, Riley E, Huettner S, Brown M, Beilenson P.

J Am Pharm Assoc (Wash). 1999 Jan-Feb;39(1):17-22.

PMID:
9990182
14.

Racial differences in acquisition of syringes from pharmacies under conditions of legal but restricted sales.

Costenbader EC, Zule WA, Coomes CC.

Int J Drug Policy. 2010 Sep;21(5):425-8. doi: 10.1016/j.drugpo.2009.12.006. Epub 2010 Jan 22.

15.

Correlates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug.

Tempalski B, Cooper HL, Friedman SR, Des Jarlais DC, Brady J, Gostnell K.

Int J Drug Policy. 2008 Apr;19 Suppl 1:S47-58. doi: 10.1016/j.drugpo.2007.11.011. Epub 2008 Mar 4.

16.

A longitudinal study of syringe acquisition by Puerto Rican injection drug users in New York and Puerto Rico: implications for syringe exchange and distribution programs.

Finlinson HA, Oliver-Vélez D, Deren S, Cant JG, Colón HM, Robles RR, Kang SY, Andía JF.

Subst Use Misuse. 2006;41(9):1313-36.

PMID:
16861181
17.

Internalized stigma and sterile syringe use among people who inject drugs in New York City, 2010-2012.

Rivera AV, DeCuir J, Crawford ND, Amesty S, Lewis CF.

Drug Alcohol Depend. 2014 Nov 1;144:259-64. doi: 10.1016/j.drugalcdep.2014.09.778. Epub 2014 Oct 2.

18.

Access to sterile syringes through San Francisco pharmacies and the association with HIV risk behavior among injection drug users.

Riley ED, Kral AH, Stopka TJ, Garfein RS, Reuckhaus P, Bluthenthal RN.

J Urban Health. 2010 Jul;87(4):534-42. doi: 10.1007/s11524-010-9468-y.

19.

Impact of pharmacy-based syringe access on injection practices among injecting drug users in Minnesota, 1998 to 1999.

Cotten-Oldenburg NU, Carr P, DeBoer JM, Collison EK, Novotny G.

J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):183-92.

PMID:
11404541
20.

Over-the-counter but out of reach: a pharmacy-based survey of OTC syringe sales in Tijuana, Mexico.

Pollini RA, Gallardo M, Ruiz S, Case P, Zaller N, Lozada R.

J Health Care Poor Underserved. 2014 May;25(2):637-51. doi: 10.1353/hpu.2014.0090.

PMID:
24858873

Supplemental Content

Support Center